M. J. Garnett

Base editing screens map mutations affecting IFNγ signalling in cancer

This study uses base editing to identify mutations affecting IFNγ signalling in cancer, revealing loss- and gain-of-function variants with clinical relevance.

A landscape of synergistic drug combinations in non-small-cell lung cancer

The paper identifies synergistic drug combinations in non-small-cell lung cancer cell lines, finding that synergy often arises from sensitizing resistant models through dual pathway targeting.

N-myristoyltransferase inhibition is synthetic lethal in MYC-deregulated cancers

N-myristoyltransferase inhibition causes mitochondrial dysfunction and cell death in MYC-deregulated cancers through post-transcriptional failure in complex I synthesis.

Agreement between two large pan-cancer CRISPR-Cas9 gene dependency datasets

This study compares two large pan-cancer CRISPR-Cas9 screens, finding high concordance in gene dependencies despite differences in protocols and reagents.

Transcription factor activities enhance markers of drug response in cancer

The paper uses computational methods to infer transcription factor activities from RNA-seq data and shows their utility as markers for drug response in cancer.

Dissecting cancer resistance to therapies with cell-type-specific dynamic logic models

The paper uses dynamic logic models of signaling pathways to predict drug sensitivity in colorectal cancer cell lines and identifies drug combinations to overcome resistance.